US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 0.699
  • -0.025-3.40%
Trading Dec 3 13:04 ET
178.76MMarket Cap-4183P/E (TTM)

Adaptimmune Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-20.58%-54.45M
208.31%47.4M
14.30%-31.95M
0.63%-140.88M
-818.71%-14.68M
6.23%-45.16M
-6.09%-43.76M
31.47%-37.28M
-1,421.36%-141.77M
-98.48%2.04M
Net income from continuing operations
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Operating gains losses
933.13%3.43M
-206.99%-571K
-45.83%305K
108.12%198K
-911.11%-511K
113.87%332K
-236.76%-186K
330.74%563K
-551.48%-2.44M
-91.63%63K
Depreciation and amortization
-2.56%2.82M
22.85%2.74M
53.39%2.83M
61.98%9.84M
99.79%2.87M
93.96%2.89M
43.81%2.23M
15.67%1.85M
-7.49%6.08M
-35.68%1.44M
Other non cash items
65.13%-106K
100.10%21K
-114.18%-19K
-2,781.62%-21.88M
-268.63%-86K
-268.89%-304K
-6,024.93%-21.63M
-39.09%134K
-30.43%816K
104.78%51K
Change In working capital
-869.73%-45.53M
-364.79%-27.35M
124.29%10.36M
-1,529.78%-24.95M
11.17%28.28M
54.01%-4.7M
-31.77%-5.89M
-246.97%-42.65M
-101.14%-1.53M
-84.57%25.44M
-Change in receivables
-473.21%-15.36M
401.87%5.17M
324.11%15.62M
86.84%-1.29M
-102.92%-582K
61.05%-2.68M
85.90%-1.71M
134.23%3.68M
49.31%-9.81M
60.35%19.97M
-Change in payables and accrued expense
-84.04%161K
198.19%8.66M
-36,528.57%-7.65M
-306.15%-9.09M
88.00%-1.3M
-56.17%1.01M
-173.92%-8.82M
-97.82%21K
4.78%4.41M
-350.05%-10.79M
-Change in other current liabilities
--1.03M
----
----
----
----
--0
----
----
----
----
-Change in other working capital
-844.41%-28.56M
-995.61%-41.64M
105.15%2.39M
-476.20%-14.57M
85.43%30.15M
46.29%-3.02M
209.11%4.65M
-1,756.35%-46.35M
-97.41%3.87M
-89.02%16.26M
Cash from discontinued investing activities
Operating cash flow
-20.58%-54.45M
208.31%47.4M
14.30%-31.95M
0.63%-140.88M
-818.71%-14.68M
6.23%-45.16M
-6.09%-43.76M
31.47%-37.28M
-1,421.36%-141.77M
-98.48%2.04M
Investing cash flow
Cash flow from continuing investing activities
-215.20%-66.02M
-127.58%-743K
-100.74%-358K
98.05%176.54M
225.49%68.2M
98.63%57.31M
-93.89%2.69M
1,112.38%48.34M
17.59%89.14M
173.54%20.95M
Net PPE purchase and sale
50.52%-143K
65.30%-422K
95.66%-102K
84.13%-4.68M
75.78%-827K
97.11%-289K
86.43%-1.22M
66.98%-2.35M
-244.02%-29.5M
14.97%-3.42M
Net intangibles purchase and sale
---292K
-1,176.92%-332K
-47.98%-256K
18.44%-199K
--0
--0
---26K
---173K
-17.87%-244K
50.00%-13K
Net business purchase and sale
--0
----
----
--45.26M
--0
--0
----
----
--0
--0
Net investment purchase and sale
-214.82%-65.7M
--0
--0
13.59%135.03M
182.25%68.81M
46.38%57.22M
-178.89%-41.87M
2,074.56%50.86M
40.55%118.88M
199.72%24.38M
Net other investing changes
-68.62%118K
----
----
--1.12M
--211K
--376K
----
----
----
----
Cash from discontinued investing activities
Investing cash flow
-215.20%-66.02M
-127.58%-743K
-100.74%-358K
98.05%176.54M
225.49%68.2M
98.63%57.31M
-93.89%2.69M
1,112.38%48.34M
17.59%89.14M
173.54%20.95M
Financing cash flow
Cash flow from continuing financing activities
4,094.80%25M
174,985.71%24.51M
14,815.82%29.24M
-93.16%880K
-94.73%74K
-58.95%596K
-99.86%14K
460.00%196K
291.33%12.87M
2,598.08%1.4M
Net issuance payments of debt
--25M
----
----
----
----
--0
----
----
----
----
Net common stock issuance
--0
--10K
15,411.17%29.16M
-95.13%624K
-99.93%1K
-69.92%435K
--0
--188K
406.80%12.82M
--1.4M
Proceeds from stock option exercised by employees
-99.38%1K
-85.71%2K
825.00%74K
412.00%256K
812.50%73K
2,583.33%161K
1,300.00%14K
-77.14%8K
-93.41%50K
-84.62%8K
Cash from discontinued financing activities
Financing cash flow
4,094.80%25M
174,985.71%24.51M
14,815.82%29.24M
-93.16%880K
-94.73%74K
-58.95%596K
-99.86%14K
460.00%196K
291.33%12.87M
2,598.08%1.4M
Net cash flow
Beginning cash position
167.68%214.68M
18.18%143.53M
34.14%147.02M
-27.73%109.6M
15.31%93.07M
-19.42%80.2M
33.08%121.44M
-27.73%109.6M
146.68%151.67M
80.83%80.71M
Current changes in cash
-849.18%-95.47M
273.35%71.17M
-127.31%-3.07M
191.88%36.54M
119.68%53.6M
171.37%12.74M
-419.86%-41.05M
119.03%11.25M
-144.27%-39.77M
-76.87%24.4M
Effect of exchange rate changes
65.89%214K
89.47%-20K
-170.75%-416K
138.15%877K
-92.21%350K
113.51%129K
95.84%-190K
146.30%588K
-729.86%-2.3M
191.31%4.49M
End cash Position
28.31%119.42M
167.68%214.68M
18.18%143.53M
34.14%147.02M
34.14%147.02M
15.31%93.07M
-19.42%80.2M
33.08%121.44M
-27.73%109.6M
-27.73%109.6M
Free cash flow
-20.77%-54.89M
203.65%46.65M
18.83%-32.31M
15.01%-145.76M
-1,018.54%-15.5M
22.17%-45.45M
10.37%-45M
35.29%-39.81M
-8,904.36%-171.51M
-101.07%-1.39M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024 (Q2)Jun 30, 2024 (Q1)Mar 31, 2024 (FY)Dec 31, 2023 (Q4)Dec 31, 2023 (Q3)Sep 30, 2023 (Q2)Jun 30, 2023 (Q1)Mar 31, 2023 (FY)Dec 31, 2022 (Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -20.58%-54.45M 208.31%47.4M 14.30%-31.95M 0.63%-140.88M -818.71%-14.68M 6.23%-45.16M -6.09%-43.76M 31.47%-37.28M -1,421.36%-141.77M -98.48%2.04M
Net income from continuing operations 61.37%-17.62M 425.03%69.52M -4,781.76%-48.5M 31.18%-113.87M -63.82%-47.92M -10.09%-45.6M 51.96%-21.39M 102.06%1.04M -4.66%-165.46M 24.73%-29.25M
Operating gains losses 933.13%3.43M -206.99%-571K -45.83%305K 108.12%198K -911.11%-511K 113.87%332K -236.76%-186K 330.74%563K -551.48%-2.44M -91.63%63K
Depreciation and amortization -2.56%2.82M 22.85%2.74M 53.39%2.83M 61.98%9.84M 99.79%2.87M 93.96%2.89M 43.81%2.23M 15.67%1.85M -7.49%6.08M -35.68%1.44M
Other non cash items 65.13%-106K 100.10%21K -114.18%-19K -2,781.62%-21.88M -268.63%-86K -268.89%-304K -6,024.93%-21.63M -39.09%134K -30.43%816K 104.78%51K
Change In working capital -869.73%-45.53M -364.79%-27.35M 124.29%10.36M -1,529.78%-24.95M 11.17%28.28M 54.01%-4.7M -31.77%-5.89M -246.97%-42.65M -101.14%-1.53M -84.57%25.44M
-Change in receivables -473.21%-15.36M 401.87%5.17M 324.11%15.62M 86.84%-1.29M -102.92%-582K 61.05%-2.68M 85.90%-1.71M 134.23%3.68M 49.31%-9.81M 60.35%19.97M
-Change in payables and accrued expense -84.04%161K 198.19%8.66M -36,528.57%-7.65M -306.15%-9.09M 88.00%-1.3M -56.17%1.01M -173.92%-8.82M -97.82%21K 4.78%4.41M -350.05%-10.79M
-Change in other current liabilities --1.03M ---- ---- ---- ---- --0 ---- ---- ---- ----
-Change in other working capital -844.41%-28.56M -995.61%-41.64M 105.15%2.39M -476.20%-14.57M 85.43%30.15M 46.29%-3.02M 209.11%4.65M -1,756.35%-46.35M -97.41%3.87M -89.02%16.26M
Cash from discontinued investing activities
Operating cash flow -20.58%-54.45M 208.31%47.4M 14.30%-31.95M 0.63%-140.88M -818.71%-14.68M 6.23%-45.16M -6.09%-43.76M 31.47%-37.28M -1,421.36%-141.77M -98.48%2.04M
Investing cash flow
Cash flow from continuing investing activities -215.20%-66.02M -127.58%-743K -100.74%-358K 98.05%176.54M 225.49%68.2M 98.63%57.31M -93.89%2.69M 1,112.38%48.34M 17.59%89.14M 173.54%20.95M
Net PPE purchase and sale 50.52%-143K 65.30%-422K 95.66%-102K 84.13%-4.68M 75.78%-827K 97.11%-289K 86.43%-1.22M 66.98%-2.35M -244.02%-29.5M 14.97%-3.42M
Net intangibles purchase and sale ---292K -1,176.92%-332K -47.98%-256K 18.44%-199K --0 --0 ---26K ---173K -17.87%-244K 50.00%-13K
Net business purchase and sale --0 ---- ---- --45.26M --0 --0 ---- ---- --0 --0
Net investment purchase and sale -214.82%-65.7M --0 --0 13.59%135.03M 182.25%68.81M 46.38%57.22M -178.89%-41.87M 2,074.56%50.86M 40.55%118.88M 199.72%24.38M
Net other investing changes -68.62%118K ---- ---- --1.12M --211K --376K ---- ---- ---- ----
Cash from discontinued investing activities
Investing cash flow -215.20%-66.02M -127.58%-743K -100.74%-358K 98.05%176.54M 225.49%68.2M 98.63%57.31M -93.89%2.69M 1,112.38%48.34M 17.59%89.14M 173.54%20.95M
Financing cash flow
Cash flow from continuing financing activities 4,094.80%25M 174,985.71%24.51M 14,815.82%29.24M -93.16%880K -94.73%74K -58.95%596K -99.86%14K 460.00%196K 291.33%12.87M 2,598.08%1.4M
Net issuance payments of debt --25M ---- ---- ---- ---- --0 ---- ---- ---- ----
Net common stock issuance --0 --10K 15,411.17%29.16M -95.13%624K -99.93%1K -69.92%435K --0 --188K 406.80%12.82M --1.4M
Proceeds from stock option exercised by employees -99.38%1K -85.71%2K 825.00%74K 412.00%256K 812.50%73K 2,583.33%161K 1,300.00%14K -77.14%8K -93.41%50K -84.62%8K
Cash from discontinued financing activities
Financing cash flow 4,094.80%25M 174,985.71%24.51M 14,815.82%29.24M -93.16%880K -94.73%74K -58.95%596K -99.86%14K 460.00%196K 291.33%12.87M 2,598.08%1.4M
Net cash flow
Beginning cash position 167.68%214.68M 18.18%143.53M 34.14%147.02M -27.73%109.6M 15.31%93.07M -19.42%80.2M 33.08%121.44M -27.73%109.6M 146.68%151.67M 80.83%80.71M
Current changes in cash -849.18%-95.47M 273.35%71.17M -127.31%-3.07M 191.88%36.54M 119.68%53.6M 171.37%12.74M -419.86%-41.05M 119.03%11.25M -144.27%-39.77M -76.87%24.4M
Effect of exchange rate changes 65.89%214K 89.47%-20K -170.75%-416K 138.15%877K -92.21%350K 113.51%129K 95.84%-190K 146.30%588K -729.86%-2.3M 191.31%4.49M
End cash Position 28.31%119.42M 167.68%214.68M 18.18%143.53M 34.14%147.02M 34.14%147.02M 15.31%93.07M -19.42%80.2M 33.08%121.44M -27.73%109.6M -27.73%109.6M
Free cash flow -20.77%-54.89M 203.65%46.65M 18.83%-32.31M 15.01%-145.76M -1,018.54%-15.5M 22.17%-45.45M 10.37%-45M 35.29%-39.81M -8,904.36%-171.51M -101.07%-1.39M
Currency Unit USD USD USD USD USD USD USD USD USD USD
Accounting Standards US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP
Audit Opinions -- -- -- Unqualified Opinion -- -- -- -- Unqualified Opinion --
Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme CAR-T Therapy
CAR-T Therapy
Intraday-0.16%